AAD > Atopic Dermatitis Risk-Benefit Profile of Baricitinib in Youngsters With Atopic Dermatitis – Out to 52 weeks, safety and efficacy data are comparable to previous findings in adults ...

AAD 2025: Almirall presents ... Klisyri has a demonstrated efficacy and safety profile, and a convenient 5-day application period, which is the shortest of any topical treatment for AK.1 ...

AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics. EP: 3.Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead. EP: 4.

The American Academy of Dermatology has created a measles resource center for dermatologists to stay prepared during the current U.S. measles outbreak. Created by the AAD’s Emerging Diseases ...

ZUG, Switzerland, March 03, 2025--Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody placulumab, and positive results from the phase 3 studies of remibrutinib.

Dr Christopher Sayed shares AAD 2025 highlights, including anticipated presentations, quick takeaways, and insights into how new research in HS affects his patients.

ORLANDO, Fla., March 07, 2025--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology presents five scientific posters at the 2025 American Academy of Dermatology ...

Paul Yamauchi, MD, PhD, discusses recent findings presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) on tildrakizumab’s efficacy for nail psoriasis, biological ...